Bronte Capital Management Pty Ltd. Alnylam Pharmaceuticals, Inc. Transaction History
Bronte Capital Management Pty Ltd.
- $847 Million
- Q3 2025
A detailed history of Bronte Capital Management Pty Ltd. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bronte Capital Management Pty Ltd. holds 34,974 shares of ALNY stock, worth $15.7 Million. This represents 1.88% of its overall portfolio holdings.
Number of Shares
34,974Holding current value
$15.7 Million% of portfolio
1.88%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
917Shares Held
117MCall Options Held
1.26MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...